

Jonas Bergh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/251560/publications.pdf>

Version: 2024-02-01

143
papers

10,788
citations

71061

41
h-index

33869

99
g-index

153
all docs

153
docs citations

153
times ranked

16599
citing authors

#	ARTICLE	IF	CITATIONS
1	Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. <i>Annals of Oncology</i> , 2015, 26, 1533-1546.	0.6	1,449
2	20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. <i>New England Journal of Medicine</i> , 2017, 377, 1836-1846.	13.9	1,052
3	A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. <i>Nature Medicine</i> , 2009, 15, 68-74.	15.2	566
4	Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 1641-1649.	0.8	555
5	Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing. <i>Nature Communications</i> , 2018, 9, 5150.	5.8	496
6	Adjuvant denosumab in breast cancer (ABCSC-18): a multicentre, randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2015, 386, 433-443.	6.3	444
7	Clinically Used Breast Cancer Markers Such As Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor 2 Are Unstable Throughout Tumor Progression. <i>Journal of Clinical Oncology</i> , 2012, 30, 2601-2608.	0.8	411
8	An HIF-1 α /VEGF-A Axis in Cytotoxic T Cells Regulates Tumor Progression. <i>Cancer Cell</i> , 2017, 32, 669-683.e5.	7.7	352
9	Caring for patients with cancer in the COVID-19 era. <i>Nature Medicine</i> , 2020, 26, 665-671.	15.2	269
10	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37,298 women with early breast cancer in 26 randomised trials. <i>Lancet</i> , 2019, 393, 1440-1452.	6.3	260
11	FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1919-1925.	0.8	248
12	First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 921-929.	0.8	244
13	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. <i>Oncogene</i> , 2018, 37, 4639-4661.	2.6	219
14	Prognostic Significance of Stromal Platelet-Derived Growth Factor β 2-Receptor Expression in Human Breast Cancer. <i>American Journal of Pathology</i> , 2009, 175, 334-341.	1.9	215
15	Digital image analysis outperforms manual biomarker assessment in breast cancer. <i>Modern Pathology</i> , 2016, 29, 318-329.	2.9	144
16	Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease. <i>Nature Communications</i> , 2019, 10, 2110.	5.8	139
17	CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment. <i>Journal of Clinical Investigation</i> , 2020, 130, 1185-1198.	3.9	139
18	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	0.5	133

#	ARTICLE	IF	CITATIONS
19	Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes. <i>Journal of Clinical Investigation</i> , 2018, 128, 1355-1370.	3.9	123
20	Increased Expression of N-myc in Human Small Cell Lung Cancer Biopsies Predicts Lack of Response to Chemotherapy and Poor Prognosis. <i>American Journal of Clinical Pathology</i> , 1987, 88, 216-220.	0.4	91
21	Highly favorable physiological responses to concurrent resistance and high-intensity interval training during chemotherapy: the OptiTrain breast cancer trial. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 93-103.	1.1	86
22	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	2.0	82
23	Long-term outcome in young women with breast cancer: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2016, 160, 131-143.	1.1	82
24	Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 1888.	3.8	79
25	miR-206 inhibits cell migration through direct targeting of the actin-binding protein Coronin 1C in triple-negative breast cancer. <i>Molecular Oncology</i> , 2014, 8, 1690-1702.	2.1	77
26	Detection of tumor-specific cytotoxic drug activity IN VITRO using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. <i>International Journal of Cancer</i> , 1994, 56, 715-720.	2.3	71
27	Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data. <i>Clinical Cancer Research</i> , 2019, 25, 5717-5726.	3.2	71
28	Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer. <i>Histopathology</i> , 2018, 72, 974-989.	1.6	70
29	High-intensity exercise during chemotherapy induces beneficial effects 12 months into breast cancer survivorship. <i>Journal of Cancer Survivorship</i> , 2019, 13, 244-256.	1.5	65
30	Expression of multiple growth factors in a human lung cancer cell line. <i>International Journal of Cancer</i> , 1987, 39, 502-507.	2.3	59
31	Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer—a prospective nationwide Swedish multicenter study. <i>Human Reproduction</i> , 2020, 35, 929-938.	0.4	58
32	Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv209.	3.0	57
33	Expression of the chemokine CXCL14 in the tumour stroma is an independent marker of survival in breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 1117-1124.	2.9	57
34	STAT3 Activity Promotes Programmed-Death Ligand 1 Expression and Suppresses Immune Responses in Breast Cancer. <i>Cancers</i> , 2019, 11, 1479.	1.7	55
35	Endothelial ALK1 Is a Therapeutic Target to Block Metastatic Dissemination of Breast Cancer. <i>Cancer Research</i> , 2015, 75, 2445-2456.	0.4	53
36	Similar Efficacy for Ovarian Ablation Compared With Cyclophosphamide, Methotrexate, and Fluorouracil: From a Randomized Comparison of Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4956-4962.	0.8	52

#	ARTICLE	IF	CITATIONS
37	Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy. <i>Cancers</i> , 2019, 11, 628.	1.7	51
38	Guidance Molecule SEMA3A Restricts Tumor Growth by Differentially Regulating the Proliferation of Tumor-Associated Macrophages. <i>Cancer Research</i> , 2016, 76, 3166-3178.	0.4	48
39	The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours. <i>Breast Cancer Research</i> , 2019, 21, 34.	2.2	48
40	Quo Vadis With Targeted Drugs in the 21st Century?. <i>Journal of Clinical Oncology</i> , 2009, 27, 2-5.	0.8	45
41	mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. <i>Cancer Letters</i> , 2015, 367, 76-87.	3.2	45
42	Safety of fertility preservation in breast cancer patients in a register-based matched cohort study. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 761-769.	1.1	45
43	The Molecular Tumor Board Portal supports clinical decisions and automated reporting for precision oncology. <i>Nature Cancer</i> , 2022, 3, 251-261.	5.7	44
44	Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts. <i>Clinical Cancer Research</i> , 2017, 23, 7512-7520.	3.2	43
45	Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study. <i>International Journal of Cancer</i> , 2018, 143, 1093-1104.	2.3	40
46	Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors. <i>Breast Cancer Research</i> , 2018, 20, 64.	2.2	40
47	Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102257.	3.4	40
48	RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2017, 17, 585-594.e4.	1.1	39
49	Microglia Induce PDGFRB Expression in Glioma Cells to Enhance Their Migratory Capacity. <i>iScience</i> , 2018, 9, 71-83.	1.9	38
50	Immune gene expression and response to chemotherapy in advanced breast cancer. <i>British Journal of Cancer</i> , 2018, 118, 480-488.	2.9	37
51	Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. <i>Breast</i> , 2012, 21, 507-513.	0.9	36
52	The European Cancer Patient's Bill of Rights, update and implementation 2016. <i>ESMO Open</i> , 2016, 1, e000127.	2.0	36
53	Separation of breast cancer and organ microenvironment transcriptomes in metastases. <i>Breast Cancer Research</i> , 2019, 21, 36.	2.2	36
54	A prospective exploration of symptom burden clusters in women with breast cancer during chemotherapy treatment. <i>Supportive Care in Cancer</i> , 2017, 25, 1423-1429.	1.0	34

#	ARTICLE	IF	CITATIONS
55	The European Medicines Agency Approval of Axitinib (Inlyta) for the Treatment of Advanced Renal Cell Carcinoma After Failure of Prior Treatment With Sunitinib or a Cytokine: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. <i>Oncologist</i> , 2015, 20, 196-201.	1.9	33
56	An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 927-936.	2.0	32
57	Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer. <i>Clinical Proteomics</i> , 2015, 12, 8.	1.1	31
58	Time-dependent risk and predictors of venous thromboembolism in breast cancer patients: A population-based cohort study. <i>Cancer</i> , 2017, 123, 468-475.	2.0	31
59	Variability in Breast Cancer Biomarker Assessment and the Effect on Oncological Treatment Decisions: A Nationwide 5-Year Population-Based Study. <i>Cancers</i> , 2021, 13, 1166.	1.7	31
60	Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications. <i>Oncotarget</i> , 2015, 6, 33306-33318.	0.8	31
61	Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 1360.	3.4	30
62	High expression of stromal PDGFR ² is associated with reduced benefit of tamoxifen in breast cancer. <i>Journal of Pathology: Clinical Research</i> , 2017, 3, 38-43.	1.3	29
63	Generation of in situ sequencing based OncoMaps to spatially resolve gene expression profiles of diagnostic and prognostic markers in breast cancer. <i>EBioMedicine</i> , 2019, 48, 212-223.	2.7	29
64	Suramin in Non-small Cell Lung Cancer and Advanced Breast Cancer: Two Parallel Phase II Studies. <i>Acta Oncologica</i> , 1997, 36, 171-174.	0.8	28
65	Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines – a Swedish survey with central re-assessment. <i>Acta Oncologica</i> , 2015, 54, 1040-1048.	0.8	27
66	Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial. <i>International Journal of Cancer</i> , 2018, 142, 618-628.	2.3	27
67	Contrast-enhanced ultrasound (CEUS) in assessing early response among patients with invasive breast cancer undergoing neoadjuvant chemotherapy. <i>Acta Radiologica</i> , 2017, 58, 394-402.	0.5	25
68	Breast cancer in young women and prognosis: How important are proliferation markers?. <i>European Journal of Cancer</i> , 2017, 84, 278-289.	1.3	24
69	MNK2 governs the macrophage antiinflammatory phenotype. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 27556-27565.	3.3	24
70	A pan-cancer analysis of the frequency of DNA alterations across cell cycle activity levels. <i>Oncogene</i> , 2020, 39, 5430-5440.	2.6	23
71	Infection-related hospitalizations in breast cancer patients: Risk and impact on prognosis. <i>Journal of Infection</i> , 2016, 72, 650-658.	1.7	22
72	Exome sequencing of primary breast cancers with paired metastatic lesions reveals metastasis-enriched mutations in the A-kinase anchoring protein family (AKAPs). <i>BMC Cancer</i> , 2018, 18, 174.	1.1	22

#	ARTICLE	IF	CITATIONS
73	CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance. <i>Scientific Reports</i> , 2019, 9, 19384.	1.6	22
74	Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. <i>Molecular Oncology</i> , 2016, 10, 517-525.	2.1	21
75	Prognostic value of Ki67 analysed by cytology or histology in primary breast cancer. <i>Journal of Clinical Pathology</i> , 2018, 71, 787-794.	1.0	21
76	Amplification of the N-myc oncogene in an adenocarcinoma of the lung. <i>Journal of Cellular Biochemistry</i> , 1986, 31, 297-304.	1.2	20
77	The European Medicines Agency Review of Pertuzumab for the Treatment of Adult Patients With HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use. <i>Oncologist</i> , 2014, 19, 766-773.	1.9	20
78	Notch signaling promotes a HIF2 α -driven hypoxic response in multiple tumor cell types. <i>Oncogene</i> , 2018, 37, 6083-6095.	2.6	20
79	Distinct Cancer-Promoting Stromal Gene Expression Depending on Lung Function. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 348-358.	2.5	20
80	Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. <i>Scientific Reports</i> , 2017, 7, 1089.	1.6	19
81	Interventional Techniques for Bone and Musculoskeletal Soft Tissue Tumors: Current Practices and Future Directions - Part I. Ablation. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 692-709.	0.4	19
82	Can Axillary Dissection be Avoided by Improved Molecular Biological Diagnosis?. <i>Acta Oncologica</i> , 2000, 39, 319-326.	0.8	18
83	Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer. <i>Onc Immunology</i> , 2018, 7, e1466017.	2.1	18
84	Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease. <i>Molecular Oncology</i> , 2020, 14, 951-963.	2.1	18
85	Impairment of endoxifen formation in tamoxifen-treated premenopausal breast cancer patients carrying reduced-function CYP2D6 alleles. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1243-1252.	1.1	18
86	Sequencing-based breast cancer diagnostics as an alternative to routine biomarkers. <i>Scientific Reports</i> , 2016, 6, 38037.	1.6	17
87	PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 7225-7231.	3.2	17
88	A randomised feasibility/phase II study (SBC 2004-1) with dose-dense/tailored epirubicin, cyclophosphamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer. <i>Acta Oncologica</i> , 2011, 50, 35-41.	0.8	16
89	Is Estradiol Monitoring Necessary in Women Receiving Ovarian Suppression for Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2016, 34, 1573-1579.	0.8	15
90	Tackling endocrine resistance in ER-positive HER2-negative advanced breast cancer: A tale of imprecision medicine. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 114, 91-101.	2.0	15

#	ARTICLE	IF	CITATIONS
91	Molecular Differences between Screen-Detected and Interval Breast Cancers Are Largely Explained by PAM50 Subtypes. <i>Clinical Cancer Research</i> , 2017, 23, 2584-2592.	3.2	15
92	A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer. <i>Breast Cancer Research</i> , 2021, 23, 8.	2.2	15
93	Pharmacogenetic impact of docetaxel on neoadjuvant treatment of breast cancer patients. <i>Pharmacogenomics</i> , 2018, 19, 1259-1268.	0.6	14
94	Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer: Results from the phase 3 PANTHER trial. <i>Cancer</i> , 2020, 126, 1175-1182.	2.0	14
95	The value of anticancer drugs – a regulatory view. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 207-215.	12.5	14
96	Characterization of A U-937 subline which can be induced to differentiate in serum-free medium. <i>International Journal of Cancer</i> , 1992, 50, 153-160.	2.3	13
97	Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer. <i>Molecular Oncology</i> , 2015, 9, 1384-1391.	2.1	13
98	Breast-cancer prevention: is the risk-benefit ratio in favour of tamoxifen?. <i>Lancet</i> , The, 2003, 362, 183-184.	6.3	12
99	The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe. <i>ESMO Open</i> , 2016, 1, e000004.	2.0	12
100	Chemotherapy, Genetic Susceptibility, and Risk of Venous Thromboembolism in Breast Cancer Patients. <i>Clinical Cancer Research</i> , 2016, 22, 5249-5255.	3.2	12
101	PD-1 protein and gene expression as prognostic factors in early breast cancer. <i>ESMO Open</i> , 2020, 5, e001032.	2.0	12
102	European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. <i>ESMO Open</i> , 2019, 4, e000570.	2.0	11
103	Efficacy and safety of cyclin dependent kinases 4/6 inhibitors in the treatment of metastatic breast cancer: a real-world experience. <i>Acta Oncologica</i> , 2020, 59, 1382-1387.	0.8	11
104	Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease. <i>Oncologist</i> , 2020, 25, e709-e715.	1.9	11
105	Risk of heart disease following treatment for breast cancer – results from a population-based cohort study. <i>ELife</i> , 2022, 11, .	2.8	11
106	Superficial scrapings from breast tumors is a source for biobanking and research purposes. <i>Laboratory Investigation</i> , 2014, 94, 796-805.	1.7	10
107	Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling. <i>BMC Cancer</i> , 2017, 17, 802.	1.1	10
108	Effect of <i>CYP2C19</i> and <i>CYP2D6</i> genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay. <i>Pharmacogenomics</i> , 2018, 19, 1027-1037.	0.6	10

#	ARTICLE	IF	CITATIONS
109	Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer. <i>Acta Oncol</i> , 2020, 59, 75-81.	0.8	10
110	Chemotherapy use near the end-of-life in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 645-651.	1.1	10
111	An Endothelial Gene Signature Score Predicts Poor Outcome in Patients with Endocrine-Treated, Low Genomic Grade Breast Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 2417-2426.	3.2	8
112	Dose intense, dose dense and tailored dose adjuvant chemotherapy for early breast cancer: an evolution of concepts. <i>Acta Oncol</i> , 2017, 56, 1143-1151.	0.8	8
113	Evidence-based prediction and prevention of cardiovascular morbidity in adults treated for cancer. <i>Cardio-Oncology</i> , 2021, 7, 20.	0.8	8
114	High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial. <i>Clinical Cancer Research</i> , 2021, 27, 3469-3477.	3.2	8
115	Interventional Techniques for Bone and Musculoskeletal Soft Tissue Tumors: Current Practices and Future Directions – Part II. Stabilization. <i>Seminars in Musculoskeletal Radiology</i> , 2020, 24, 710-725.	0.4	8
116	Adjuvant chemotherapy for breast cancer – one fits all? <i>Breast</i> , 2005, 14, 564-569.	0.9	7
117	Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology. <i>Journal of Clinical Oncology</i> , 2017, 35, 254-255.	0.8	7
118	European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma. <i>ESMO Open</i> , 2020, 5, e000798.	2.0	6
119	Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 87-96.	1.1	6
120	A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 15-23.	1.1	6
121	Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer. <i>Cancers</i> , 2021, 13, 4655.	1.7	6
122	Effects of Interferons and Tumour Necrosis Factor- α on Human Lung Cancer Cell Lines and the Development of an Interferon-Resistant Lung Cancer Cell Line. <i>Acta Oncol</i> , 1996, 35, 473-478.	0.8	5
123	Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 349-355.	1.1	5
124	Leukocyte nadir as a predictive factor for efficacy of adjuvant chemotherapy in breast cancer. Results from the prospective trial SBC 2000-1. <i>Acta Oncol</i> , 2020, 59, 825-832.	0.8	5
125	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. <i>Cancer Research</i> , 2022, 82, GS1-01-GS1-01.	0.4	5
126	Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution. <i>Cancers</i> , 2022, 14, 1999.	1.7	5

#	ARTICLE	IF	CITATIONS
127	MICADo – Looking for Mutations in Targeted PacBio Cancer Data: An Alignment-Free Method. <i>Frontiers in Genetics</i> , 2016, 7, 214.	1.1	4
128	Is There a Role for Intensive Therapy in Breast Cancer?. <i>Acta Oncologica</i> , 1999, 38, 37-46.	0.8	3
129	Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm-Gotland cancer registry. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 703-712.	1.1	3
130	Long-Term Prognostication for 2014 Women With Small and Node-Negative Breast Cancer, (T1abN0). <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa084.	1.4	3
131	Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study. <i>Npj Breast Cancer</i> , 2021, 7, 144.	2.3	3
132	Erratum to – How to treat male breast cancer [The Breast 16S2 (2007) S147–S154]. <i>Breast</i> , 2008, 17, 319-319.	0.9	2
133	Outcome and presentation of heart failure in breast cancer patients: findings from a Swedish register-based study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, 6, 147-155.	1.8	2
134	CD11c-CD8 Spatial Cross Presentation: A Novel Approach to Link Immune Surveillance and Patient Survival in Soft Tissue Sarcoma. <i>Cancers</i> , 2021, 13, 1175.	1.7	2
135	RE: Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1280-1281.	3.0	1
136	Feasibility of reusing time-matched controls in an overlapping cohort. <i>Statistical Methods in Medical Research</i> , 2018, 27, 1818-1829.	0.7	1
137	Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects. <i>ESMO Open</i> , 2020, 5, e000856.	2.0	1
138	Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 451-462.	1.1	1
139	Chemotherapy of Breast Cancer. <i>American Journal of Cancer</i> , 2002, 1, 165-171.	0.4	0
140	Sisyphus Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies. <i>Journal of Clinical Oncology</i> , 2016, 34, 895-897.	0.8	0
141	Reply to A.Y. Lin. <i>Journal of Clinical Oncology</i> , 2017, 35, 121-122.	0.8	0
142	Safety and efficacy of eribulin in patients with advanced breast cancer treated outside of a clinical trial: A single institution experience.. <i>Journal of Clinical Oncology</i> , 2012, 30, e11510-e11510.	0.8	0
143	Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study. <i>Breast Cancer Research and Treatment</i> , 2022, , 1.	1.1	0